Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ascendis Pharma (ASND)
NASDAQ:ASND
Holding ASND?
Track your performance easily
ASND Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$90.13 - $161.00
Previous Close$124.38
Volume17.73K
Average Volume (3M)641.68K
Market Cap
$7.41B
Enterprise Value$7.70B
Total Cash (Recent Filing)€399.44M
Total Debt (Recent Filing)€644.26M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Apr 02, 2025EPS Estimate
-$1.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.10
Shares Outstanding56,614,385
10 Day Avg. Volume609,236
30 Day Avg. Volume641,684
Standard Deviation0.12
R-Squared0.09
Alpha0.00072
Financial Highlights & Ratios
Price to Book (P/B)-48.40
Price to Sales (P/S)23.70
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$190.85Price Target Upside54.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Ascendis Pharma News
PremiumCompany Announcements
Ascendis Pharma Reports Strong Q3 2024 ResultsBulls Say, Bears Say
Bulls Say
Market ExpansionPlans to expand Skytrofa's footprint to additional short stature indications which management believes could fuel sales growth.
Product LaunchThe upcoming US Yorvipath launch is seen as a significant opportunity and is expected to exceed market expectations.
Strategic PartnershipASND announced the company has entered an exclusive worldwide license agreement with Novo Nordisk to develop proprietary products using the TransCon platform for metabolic and cardiovascular diseases.
Bears Say
Competitive ThreatsAn oral competitor, infigratinib, could potentially become the dominant therapy for achondroplasia due to its more convenient dosing profile.
Financial PerformanceThe valuation multiple used by the analyst has decreased from 35x to 25x, suggesting a less aggressive growth expectation.
Management ExecutionThe Skytrofa revenue miss and guidance revision highlight management's execution, which investors see as a risk to the US Yorvipath launch.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $90.13 and its highest was $161.00 in the past 12 months.
What is Ascendis Pharma’s market cap?
Currently, no data Available
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is Apr 02, 2025 which is in 132 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Nov 14, 2024. The company reported -$1.814 earnings per share for the quarter, missing the consensus estimate of -$1.65 by -$0.163.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is -$1.32.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 60,231,483 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$1.814 in its last earnings report, missing expectations of -$1.65. Following the earnings report the stock price went up 1.794%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Among the largest hedge funds holding Ascendis Pharma’s share is RA Capital Management. It holds Ascendis Pharma’s shares valued at 1B.
---
Ascendis Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$190.85 (54.07% Upside)
$190.85 (54.07% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 113.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
32.04%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
---
ASND Earnings Call
Q3 2024
0:00 / 0:00
---
ASND Stock 12 Month Forecast
Average Price Target
$190.85
▲(54.07% Upside)
Technical Analysis
Best Analysts Covering ASND
1 Year
1 Year Success Rate
16/27 ratings generated profit
1 Year Average Return
+21.05%
reiterated a buy rating 7 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 59.26% of your transactions generating a profit, with an average return of +21.05% per trade.
---